🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

BriaCell’s most recent Phase 2 study cohort of 25 patients* achieved a 52% one-year survival rate. 11 of these patients remain alive as of most recent contact, including one patient at 38.3 months and another at 30.3 months. Learn more: bit.ly/3Ggl83o $BCTX $BCTXW

Adam M. Brufsky, MD, PhD, FACP, Professor of Medicine at the @PittHeatlthSci & Medical Director of the Magee-Women's Cancer Program comments on BriaCell's recently reported updated survival data from its Phase 2 study of Bria-IMT. bit.ly/3Ggl83o $BCTX $BCTXW

$BCTX announced the sustained complete resolution of lung metastasis in a patient with #metastaticbreastcancer (#MBC) treated with Bria-OTS, BriaCell’s personalized off the shelf #immunotherapy. bit.ly/4nECbwA $BCTXW

BriaCell’s first Bria-OTS study patient, a 78-year-old woman with advanced disease and multiple prior treatment failures, achieved 100% resolution of a lung metastasis following BriaCell’s Bria-OTS monotherapy. bit.ly/4nECbwA $BCTX $BCTXW

“These results represent an exciting clinical milestone in the Bria-OTS program,” said Dr. Neal S. Chawla, Director at the Sarcoma Oncology in Santa Monica, CA, and Principal Investigator of the Bria-OTS study. Learn more: bit.ly/4nECbwA $BCTX $BCTXW

BriaCell announced updated results from its Phase 2 study of Bria-IMT™ in combination with #checkpointinhibitor in patients with advanced #metastaticbreastcancer (#MBC). Find more information: bit.ly/4ljhhBA $BCTX $BCTXW

BriaCell is pleased to report the sustained complete resolution of temporal lobe brain metastasis and continued orbital (behind the eye) tumor reduction in the Phase 2 study in #MBC. bit.ly/4ljhhBA $BCTX $BCTXW #metastaticbreastcancer

BriaCell announced updated Phase 2 survival data for its lead #immunotherapy candidate, Bria-IMT, in combination with an immune #checkpointinhibitor (#CPI). For more information, visit: bit.ly/44q98pd $BCTX $BCTXW #metastaticbreastcancer #MBC

BriaCell’s ongoing pivotal Phase 3 clinical study, evaluating Bria-IMT, plus immune CPI versus physician's choice in advanced #metastaticbreastcancer, currently has 58 active clinical sites across 15 states. For more information, please visit: bit.ly/3ZZg8a1 $BCTX $BCTXW

"BriaCell’s survival data in single arm Phase 2 trial highlights the potential activity of Bria-IMT in combination with CPIs and is subject to ongoing investigation in a Phase 3 randomized clinical trial in MBC," said Aditya Bardia, MD, MPH, FASCO , a leading #breastcancer

BriaCell announced the addition of a key clinical site, Mayo Clinic, to its ongoing pivotal Phase 3 clinical study in #metastaticbreastcancer. Find additional details: bit.ly/46GYCev $BCTX $BCTXW

“We are very excited to be working with renowned clinical experts at a leading cancer center like Mayo Clinic, who also participated in BriaCell's Phase 2 study,” comments Dr. Giuseppe Del Priore, BriaCell’s CMO. To learn more, please visit: bit.ly/46GYCev BCTX $BCTXW

Survival benefit was observed in heavily pre-treated patients, including those who failed treatment with checkpoint inhibitors (CPIs) and antibody-drug conjugates (ADCs). Learn more: bit.ly/3Ggl83o $BCTX $BCTXW #metastaticbreastcancer #breastcancer #MBC

BriaCell President and CEO Dr. William V. Williams comments on the complete resolution of lung metastasis observed in the first patient treated with BriaCell's Bria-OTS Phase 1/2a study. Learn more: bit.ly/4nECbwA $BCTX $BCTXW #metastaticbreastcancer #breastcancer

“We are thrilled to see our Bria-IMT regimen outperform established benchmarks like Trodelvy in TNBC and HR+ MBC patients,” stated Dr. William V. Williams, BriaCell’s President and CEO. Find BriaCell's updated Phase 2 survival data, here: bit.ly/44q98pd $BCTX $BCTXW

BriaCell announces two clinical data poster presentations at the European Society for Medical Oncology (ESMO) Congress 2025 Annual Meeting taking place October 17 – 21 in Berlin, Germany. Find additional details: bit.ly/4o56Fbp $BCTX $BCTXW #ESMO25